Astrazeneca (AZN) Total Debt (2009 - 2026)

Astrazeneca has reported Total Debt for 18 years, with the latest figure at -$17.9 billion in Q1 2026.

• On a quarterly basis, Total Debt fell 121.32% year-over-year to -$17.9 billion in Q1 2026; TTM through Mar 2026 was -$17.9 billion, a 121.32% decrease from a year earlier, with the FY2025 full-year figure at -$13.0 million, up 77.97% from the prior year.
• Total Debt was -$17.9 billion for Q1 2026 at Astrazeneca, down from -$13.0 million in the prior quarter.
• The five-year high for Total Debt was -$13.0 million in Q4 2025, with the low at -$17.9 billion in Q1 2026.
• Average Total Debt over 5 years is -$6.7 billion, with a median of -$6.2 billion recorded in 2022.
• The largest YoY upside for Total Debt was 77.97% in 2025 against a maximum downside of 319.36% in 2025.
• Over 5 years, Total Debt stood at -$183.0 million in 2022, then dropped by 10.93% to -$203.0 million in 2023, then jumped by 70.94% to -$59.0 million in 2024, then soared by 77.97% to -$13.0 million in 2025, then plunged by 137953.85% to -$17.9 billion in 2026.
• The last three Total Debt figures came in at -$17.9 billion (Q1 2026), -$13.0 million (Q4 2025), and -$13.8 billion (Q3 2025), per Business Quant data.